\BOOKMARK [1][-]{section.0.1}{Introduction}{}% 1
\BOOKMARK [2][-]{subsection.0.1.1}{Design of CAR T Cell}{section.0.1}% 2
\BOOKMARK [3][-]{subsubsection.0.1.1.1}{Spacer Domain}{subsection.0.1.1}% 3
\BOOKMARK [1][-]{section.0.2}{Current Understanding}{}% 4
\BOOKMARK [2][-]{subsection.0.2.1}{Major Target}{section.0.2}% 5
\BOOKMARK [2][-]{subsection.0.2.2}{Toxicity}{section.0.2}% 6
\BOOKMARK [3][-]{subsubsection.0.2.2.1}{Cytokine Release Syndrome \(CRS\)}{subsection.0.2.2}% 7
\BOOKMARK [3][-]{subsubsection.0.2.2.2}{Neurotoxicity}{subsection.0.2.2}% 8
\BOOKMARK [3][-]{subsubsection.0.2.2.3}{Anaphylaxis}{subsection.0.2.2}% 9
\BOOKMARK [3][-]{subsubsection.0.2.2.4}{On-Target/Off-Tumour}{subsection.0.2.2}% 10
\BOOKMARK [1][-]{section.0.3}{Future CAR development}{}% 11
\BOOKMARK [2][-]{subsection.0.3.1}{Challenges in Designing CAR T-Cell for Solid Tumours}{section.0.3}% 12
\BOOKMARK [3][-]{subsubsection.0.3.1.1}{Trafficking}{subsection.0.3.1}% 13
\BOOKMARK [3][-]{subsubsection.0.3.1.2}{Infiltration}{subsection.0.3.1}% 14
\BOOKMARK [3][-]{subsubsection.0.3.1.3}{Microenvironment}{subsection.0.3.1}% 15
\BOOKMARK [2][-]{subsection.0.3.2}{Additional Tools}{section.0.3}% 16
\BOOKMARK [3][-]{subsubsection.0.3.2.1}{Safety/Efficacy Monitoring: Organoid}{subsection.0.3.2}% 17
\BOOKMARK [3][-]{subsubsection.0.3.2.2}{Incorporation of Transcriptomics/Proteomics Data}{subsection.0.3.2}% 18
\BOOKMARK [1][-]{section.0.4}{Conclusion}{}% 19
